Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.3
Journals
Nanomaterials
Special Issues
Isotopes Labeled Nanoparticles
share announcement

Isotopes Labeled Nanoparticles

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: closed (20 March 2021) | Viewed by 15161

Special Issue Editors

Prof. Dr. Aleksander Bilewicz

E-Mail Website
Guest Editor
Institute of Nuclear Chemistry and Technology, Warsaw, Warsaw, Poland
Interests: nuclear chemistry; radiopharmacy; alpha and Auger electron emitters in nuclear medicine; PET radiopharmaceuticals; radionuclide labelled nanoparticles; relativistic effects in chemistry; transactinide chemistry
Dr. Penelope Bouziotis

E-Mail Website
Co-Guest Editor
Radiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos, Athens, Greece
Interests: nanoparticles; theranostics; PET/SPECT/MR Imaging; radiolabeled nanoparticles; nanobrachytherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recently, there has been an increasing amount of interest in nanomaterials for diagnostic and therapeutic applications. Radionuclides with specific emission properties can be incorporated into nanoparticles (NPs) and used for radionuclide therapy and radio-imaging. The advantage of NPs is their potential for containing several radioactive atoms within a single carrier. NPs can deliver radionuclides using either passive or active targeting strategy. The passive targeting accumulation of NPs takes place in nonspecific ways through enlarged gap junctions in tumor endothelial cells. This type of targeting, which enables macromolecules to selectively accumulate in the tumor tissue, is called enhanced permeation and retention (EPR). Unfortunately, local drug deposition is unfeasible for larger tumors with poor vascularization and for floating cancers such as lymphoma and leukemia. Target specificity is then achieved through hybrid NPs produced by conjugating NPs with tumor-specific biomolecules, including mAbs, aptamers, peptides, or various receptor-specific substrates. Recently, there has been a growing interest in the use of radionuclide-labeled nanoparticles to directly deliver corpuscular radiation to the tumor, such as in brachytherapy; thus, such technology using nanoparticles is called nanobrachytherapy. In this perspective, radioactive nanoparticles could represent a promising alternative to current brachytherapy methods with outstanding results compared to conventional brachytherapy.

Prof. Dr. Aleksander Bilewicz
Dr. Penelope Bouziotis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Radiopharmacy
  • Radionuclides
  • Radiolabeled nanoparticles
  • PET imaging
  • Radioimmunotherapy

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 4089 KiB  
Article
Chelator-Free/Chelator-Mediated Radiolabeling of Colloidally Stabilized Iron Oxide Nanoparticles for Biomedical Imaging
by Sofia Papadopoulou, Argiris Kolokithas-Ntoukas, Evangelia-Alexandra Salvanou, Anastasios Gaitanis, Stavros Xanthopoulos, Konstantinos Avgoustakis, Maria Gazouli, Maria Paravatou-Petsotas, Charalampos Tsoukalas, Aristides Bakandritsos and Penelope Bouziotis
Nanomaterials 2021, 11(7), 1677; https://doi.org/10.3390/nano11071677 - 25 Jun 2021
Cited by 11 | Viewed by 2627
Abstract
The aim of this study was to develop a bioimaging probe based on magnetic iron oxide nanoparticles (MIONs) surface functionalized with the copolymer (p(MAA-g-EGMA)), which were radiolabeled with the positron emitter Gallium-68. The synthesis of the hybrid MIONs was realized by hydrolytic condensation [...] Read more.
The aim of this study was to develop a bioimaging probe based on magnetic iron oxide nanoparticles (MIONs) surface functionalized with the copolymer (p(MAA-g-EGMA)), which were radiolabeled with the positron emitter Gallium-68. The synthesis of the hybrid MIONs was realized by hydrolytic condensation of a single ferrous precursor in the presence of the copolymer. The synthesized MagP MIONs displayed an average Dh of 87 nm, suitable for passive targeting of cancerous tissues through the enhanced permeation and retention (EPR) effect after intravenous administration, while their particularly high magnetic content ascribes strong magnetic properties to the colloids. Two different approaches were explored to develop MIONs radiolabeled with 68Ga: the chelator-mediated approach, where the chelating agent NODAGA-NHS was conjugated onto the MIONs (MagP-NODAGA) to form a chelate complex with 68Ga, and the chelator-free approach, where 68Ga was directly incorporated onto the MIONs (MagP). Both groups of NPs showed highly efficient radiolabeling with 68Ga, forming constructs which were stable with time, and in the presence of PBS and human serum. Ex vivo biodistribution studies of [68Ga]Ga- MIONs showed high accumulation in the mononuclear phagocyte system (MPS) organs and satisfactory blood retention with time. In vivo PET imaging with [68Ga]Ga-MagP MIONs was in accordance with the ex vivo biodistribution results. Finally, the MIONs showed low toxicity against 4T1 breast cancer cells. These detailed studies established that [68Ga]Ga- MIONs exhibit potential for application as tracers for early cancer detection. Full article
(This article belongs to the Special Issue Isotopes Labeled Nanoparticles)
►▼ Show Figures

Graphical abstract

20 pages, 5213 KiB  
Article
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
by Weronika Gawęda, Marek Pruszyński, Edyta Cędrowska, Magdalena Rodak, Agnieszka Majkowska-Pilip, Damian Gaweł, Frank Bruchertseifer, Alfred Morgenstern and Aleksander Bilewicz
Nanomaterials 2020, 10(10), 2067; https://doi.org/10.3390/nano10102067 - 20 Oct 2020
Cited by 23 | Viewed by 3299
Abstract
Barium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for 223Ra radionuclide in targeted α-therapy. BaFe nanoparticles were labeled using a hydrothermal Ba2+ cations replacement by 223Ra with yield reaching 61.3 ± 1.8%. Radiolabeled nanoparticles were functionalized with 3-phosphonopropionic acid (CEPA) [...] Read more.
Barium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for 223Ra radionuclide in targeted α-therapy. BaFe nanoparticles were labeled using a hydrothermal Ba2+ cations replacement by 223Ra with yield reaching 61.3 ± 1.8%. Radiolabeled nanoparticles were functionalized with 3-phosphonopropionic acid (CEPA) linker followed by covalent conjugation to trastuzumab (Herceptin®). Thermogravimetric analysis and radiometric method with the use of [131I]-labeled trastuzumab revealed that on average 19–21 molecules of trastuzumab are attached to the surface of one BaFe–CEPA nanoparticle. The hydrodynamic diameter of BaFe–CEPA–trastuzumab conjugate is 99.9 ± 3.0 nm in water and increases to 218.3 ± 3.7 nm in PBS buffer, and the zeta potential varies from +27.2 ± 0.7 mV in water to −8.8 ± 0.7 in PBS buffer. The [223Ra]BaFe–CEPA–trastuzumab radiobioconjugate almost quantitatively retained 223Ra (>98%) and about 96% of 211Bi and 94% of 211Pb over 30 days. The obtained radiobioconjugate exhibited high affinity, cell internalization and cytotoxicity towards the human ovarian adenocarcinoma SKOV-3 cells overexpressing HER2 receptor. Confocal studies indicated that [223Ra]BaFe–CEPA–trastuzumab was located in peri-nuclear space. High cytotoxicity of the [223Ra]BaFe–CEPA–trastuzumab bioconjugate was confirmed by radiotoxicity studies on SKOV-3 cell monolayers and 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient. Full article
(This article belongs to the Special Issue Isotopes Labeled Nanoparticles)
►▼ Show Figures

Figure 1

14 pages, 4454 KiB  
Article
Head-To-Head Comparison of Biological Behavior of Biocompatible Polymers Poly(Ethylene Oxide), Poly(2-Ethyl-2-Oxazoline) and Poly[N-(2-Hydroxypropyl)Methacrylamide] as Coating Materials for Hydroxyapatite Nanoparticles in Animal Solid Tumor Model
by Zbynek Novy, Volodymyr Lobaz, Martin Vlk, Jan Kozempel, Petr Stepanek, Miroslav Popper, Jana Vrbkova, Marian Hajduch, Martin Hruby and Milos Petrik
Nanomaterials 2020, 10(9), 1690; https://doi.org/10.3390/nano10091690 - 27 Aug 2020
Cited by 6 | Viewed by 2130
Abstract
Nanoparticles (NPs) represent an emerging platform for diagnosis and treatment of various diseases such as cancer, where they can take advantage of enhanced permeability and retention (EPR) effect for solid tumor accumulation. To improve their colloidal stability, prolong their blood circulation time and [...] Read more.
Nanoparticles (NPs) represent an emerging platform for diagnosis and treatment of various diseases such as cancer, where they can take advantage of enhanced permeability and retention (EPR) effect for solid tumor accumulation. To improve their colloidal stability, prolong their blood circulation time and avoid premature entrapment into reticuloendothelial system, coating with hydrophilic biocompatible polymers is often essential. Most studies, however, employ just one type of coating polymer. The main purpose of this study is to head-to-head compare biological behavior of three leading polymers commonly used as “stealth” coating materials for biocompatibilization of NPs poly(ethylene oxide), poly(2-ethyl-2-oxazoline) and poly[N-(2-hydroxypropyl)methacrylamide] in an in vivo animal solid tumor model. We used radiolabeled biodegradable hydroxyapatite NPs as a model nanoparticle core within this study and we anchored the polymers to the NPs core by hydroxybisphosphonate end groups. The general suitability of polymers for coating of NPs intended for solid tumor accumulation is that poly(2-ethyl-2-oxazoline) and poly(ethylene oxide) gave comparably similar very good results, while poly[N-(2-hydroxypropyl)methacrylamide] was significantly worse. We did not observe a strong effect of molecular weight of the coating polymers on tumor and organ accumulation, blood circulation time, biodistribution and biodegradation of the NPs. Full article
(This article belongs to the Special Issue Isotopes Labeled Nanoparticles)
►▼ Show Figures

Figure 1

12 pages, 1066 KiB  
Article
Hydroxyapatite and Titanium Dioxide Nanoparticles: Radiolabelling and In Vitro Stability of Prospective Theranostic Nanocarriers for 223Ra and 99mTc
by Petra Suchánková, Ekaterina Kukleva, Eva Nykl, Pavel Nykl, Michal Sakmár, Martin Vlk and Ján Kozempel
Nanomaterials 2020, 10(9), 1632; https://doi.org/10.3390/nano10091632 - 20 Aug 2020
Cited by 16 | Viewed by 2447
Abstract
Hydroxyapatite and titanium dioxide are widely used materials in a broad spectrum of branches. Due to their appropriate properties such as a large specific surface area, radiation stability or relatively low toxicity, they could be potentially used as nanocarriers for medicinal radionuclides for [...] Read more.
Hydroxyapatite and titanium dioxide are widely used materials in a broad spectrum of branches. Due to their appropriate properties such as a large specific surface area, radiation stability or relatively low toxicity, they could be potentially used as nanocarriers for medicinal radionuclides for diagnostics and therapy. Two radiolabelling strategies of both nanomaterials were carried out by 99mTc for diagnostic purposes and by 223Ra for therapeutic purposes. The first one was the radionuclide sorption on ready-made nanoparticles and the second one was direct radionuclide incorporation into the structure of the nanoparticles. Achieved labelling yields were higher than 94% in all cases. Afterwards, in vitro stability tests were carried out in several solutions: physiological saline, bovine blood plasma, bovine blood serum, 1% and 5% human albumin solutions. In vitro stability studies were performed as short-term (59 h for 223Ra and 31 h for 99mTc) and long-term experiments (five half-lives of 223Ra, approx. 55 days). Both radiolabelled nanoparticles with 99mTc have shown similar released activities (about 20%) in all solutions. The best results were obtained for 223Ra radiolabelled titanium dioxide nanoparticles, where overall released activities were under 6% for 59 h study in all matrices and under 3% for 55 days in a long-term perspective. Full article
(This article belongs to the Special Issue Isotopes Labeled Nanoparticles)
►▼ Show Figures

Figure 1

Review

Jump to: Research

25 pages, 2329 KiB  
Review
Nanoparticles in Targeted Alpha Therapy
by Agnieszka Majkowska-Pilip, Weronika Gawęda, Kinga Żelechowska-Matysiak, Kamil Wawrowicz and Aleksander Bilewicz
Nanomaterials 2020, 10(7), 1366; https://doi.org/10.3390/nano10071366 - 13 Jul 2020
Cited by 23 | Viewed by 4062
Abstract
Recent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery. [...] Read more.
Recent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery. In this publication, we provide a comprehensive overview of available information on functional nanomaterials for targeted alpha therapy. The first section describes why nanoconstructs are used for the synthesis of α-emitting radiopharmaceuticals. Next, we present the synthesis and summarise the recent studies demonstrating therapeutic applications of α-emitting labelled radiobioconjugates in targeted therapy. Finally, future prospects and the emerging possibility of therapeutic application of radiolabelled nanomaterials are discussed. Full article
(This article belongs to the Special Issue Isotopes Labeled Nanoparticles)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop